Global EditionASIA 中文雙語Fran?ais
    Opinion
    Home / Opinion / Op-Ed Contributors

    Liquid biopsy technology key to early screening for cancer

    By Sizhen Wang | chinadaily.com.cn | Updated: 2021-02-04 14:18
    Share
    Share - WeChat
    Poster from worldcancerday.org 

    The year 2020 will go down in history as a period when the COVID-19 pandemic claimed the lives of more than two million people worldwide in 12 months. Just entering the 2021, the International Agency for Research on Cancer of the World Health Organization gave the public an even more frightening statistic: there were 19.29 million new cancer cases and 9.96 million cancer deaths globally in 2020. 

    At the same time, limited public health resources have also affected the research, prevention and treatment of cancers while responding to the pandemic, according to a report by The Union for International Cancer Control. Moreover, as the COVID-19 pandemic continues to impact the income of many people, more families are under greater financial pressure, which is undoubtedly making it more difficult for cancer patients to receive sustainable and effective cancer treatments.

    While the COVID-19 virus has greatly impacted public health, cancer remains a more severe threat. How to deal with the threat of cancer economically and efficiently is a common issue that the world needs to consider both during and after our recovery from the pandemic.

    The good news is that the COVID-19 pandemic has served as a very important reminder that scientific screening technologies and strategies are essential for the prevention and control of major diseases. Cary Adams, CEO of UICC, emphasized on this year’s World Cancer Day.

    "Let us all aim in 2021 to refocus our collective efforts on the long-term challenges that cancer poses to every country in the world. We must prevent more, diagnose earlier, and ensure that all people living with cancer have access to the quality treatment they need."

    With a mission of "fighting against cancer to safeguard life", Genetron Health believes that liquid biopsy technology will help promote and implement early cancer screening for everyone, and achieve the transformation and innovation of cancer treatment for a new era, which resonates with the theme of this year's World Cancer Day, "I am and I will".

    The scientific community recognizes that an effective way to increase the cure rate for cancer patients, and to reduce the pain and financial burden of patients, is to conduct early diagnosis and treatment in the early stages of cancer. As a result, the awareness of early cancer screening for high-risk groups has increased significantly in many countries. The world's leading cancer precision medicine innovation companies are increasing the research and development of early screening technologies. One of the main trends is the investment in liquid biopsy technology.

    Liquid biopsy refers to a test that analyzes the body by detecting biomarkers in human fluids, including blood, urine, and cerebrospinal fluid. It is widely used in non-invasive prenatal testing, genetic disease screening and other fields. Compared with traditional biopsy methods, liquid biopsy does not require tissue puncture, but uses non-invasive specimens such as blood and urine to diagnose and evaluate diseases via high-throughput sequencing technologies. At the same time, liquid biopsy has the advantages of reduced side effects, simpler operation, re-sampling, and relatively low cost.

    In recent years, with the continuous development of technology, liquid biopsy has shown promising application prospects in the field of early cancer screening. Compared with conventional screening methods such as imaging, it is more advanced in precision, accessibility, non-invasiveness and standardization. However, as of now, no country or company has been able to commercialize NGS-based tumor liquid biopsy technology for early screening on a large scale. Globally, NGS-based liquid biopsy for early cancer screening is still in the stage of technology and product upgrade optimization.

    Despite a late start in the field of biotechnology, thanks to the active guidance and support of national policies, Chinese innovation companies in biotech have made many achievements in various technical fields. In particular, the field of liquid biopsy has witnessed world-leading breakthroughs. For example, in terms of the research and development of liquid biopsy early screening technology for liver cancer, Chinese companies have taken the lead in publishing large-scale prospective cohort research results in international journals, and the data results are world class.

    The innovative original technology of Chinese biotechnology companies in the field of liquid biopsy for early screening of cancer allows more tests with fewer blood samples to ensure more diverse information about the tumor and the accuracy of each result. Based on these original technologies, Chinese companies have developed an early screening product for liver cancer, which performed better than current medical standards (ultrasound plus with alpha-fetoprotein) in the FDA prospective cohort study. As a result, it has been recognized as a "Breakthrough Medical Device" by the FDA.

    2021 is the final year of the World Cancer Day three-year "I am and I will"-themed campaign. It also encourages everyone to act together and cooperate in the fight against cancer (2021: Together, all our actions matter).

    Only by realizing product inclusiveness and large-scale application can we truly realize the comprehensive promotion of early cancer screening through technological innovation. We are also pleased to see that in the Chinese market, which has the largest number of cancer patients in the world, early screening products based on liquid biopsy technology have the advantage of lower cost and higher accuracy. Application is proceeding on three major commercial paths, including medical examination institutions, the hospital market, and government livelihood projects.

    Sizhen Wang is the co-founder and CEO of Genetron Health.

    The opinions expressed here are those of the writer and do not necessarily represent the views of China Daily and China Daily website.

    If you have a specific expertise and would like to contribute to China Daily, please contact us at opinion@chinadaily.com.cn, and comment@chinadaily.com.cn.

    Most Viewed in 24 Hours
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    国产高清中文欧美| 亚洲成在人线在线播放无码 | AV色欲无码人妻中文字幕| 极品粉嫩嫩模大尺度无码视频| 中文字幕视频在线免费观看| 亚洲AV无码一区二区大桥未久| 亚洲av无码一区二区三区乱子伦| 狠狠躁天天躁无码中文字幕| 国产网红主播无码精品 | 日韩精品人妻系列无码专区免费| 最近中文字幕视频在线资源| 人看的www视频中文字幕| 精品三级AV无码一区| 亚洲成A人片在线观看无码不卡| 日本一区二区三区精品中文字幕| 人妻一区二区三区无码精品一区| 日韩免费无码视频一区二区三区| 成人无码a级毛片免费| 最新版天堂资源中文网| 五月天中文字幕mv在线| 中文字幕精品亚洲无线码一区| 国产a v无码专区亚洲av| 无码av最新无码av专区| 无码一区二区三区免费| 亚洲午夜国产精品无码| 少妇性饥渴无码A区免费| 69堂人成无码免费视频果冻传媒| 免费无码国产在线观国内自拍中文字幕 | 亚洲AⅤ永久无码精品AA| AV大片在线无码永久免费| 无码国产精品一区二区免费模式 | 亚洲爆乳无码一区二区三区| 免费无码又爽又刺激网站直播 | 久久AV无码精品人妻糸列| 特级做A爰片毛片免费看无码| 免费无码国产在线观国内自拍中文字幕 | 狠狠噜天天噜日日噜无码| 精品无码AV一区二区三区不卡 | 久久受www免费人成_看片中文| 亚洲精品无码专区2| 超清中文乱码字幕在线观看|